title: Cilostazol decreases total atrial conduction time in patients with peripheral artery disease.
abstract: OBJECTIVE
  Total atrial conduction time (TACT) is the most important parameter in predicting the development of new-onset atrial fibrillation. We investigated the effect of cilostazol therapy on TACT in patients with peripheral artery disease.
  
  
  METHODS
  Thirty patients with peripheral artery disease were treated with cilostazol (200 mg/day) for 6 months. The baseline echocardiographic total atrial conduction time parameter was compared with the 6-month follow-up.
  
  
  RESULTS
  The TACT duration was decreased in all patients compared with the baseline after therapy (121.8 ± 19.3 vs. 109.1 ± 15.9 milliseconds, p<0.001). However, left atrial (LA) diameter was not changed with the therapy. The reduction of TACT duration was correlated with the increase in mitral E wave velocity/mitral A wave velocity ratio (r=-0.48, p<0.003).
  
  
  CONCLUSIONS
  Our results showed that 200 mg cilostazol treatment decreased TACT duration in patients with peripheral artery disease, which may also prevent the development and/or recurrence of atrial fibrillation (AF).
authors.affiliation: Kartal Koşuyolu Heart & Research Hospital, Cardiology Clinic, Kartal, İstanbul, Turkey.
authors.forename: E
authors.initials: E
authors.lastname: Alizade
authors.forename: M
authors.initials: M
authors.lastname: Sahin
authors.forename: Z
authors.initials: Z
authors.lastname: Simşek
authors.forename: G
authors.initials: G
authors.lastname: Açar
authors.forename: M
authors.initials: M
authors.lastname: Bulut
authors.forename: A
authors.initials: A
authors.lastname: Güler
authors.forename: A
authors.initials: A
authors.lastname: Avcı
authors.forename: M E
authors.initials: ME
authors.lastname: Kalkan
authors.forename: S
authors.initials: S
authors.lastname: Pala
authors.forename: M
authors.initials: M
authors.lastname: Akçakoyun
authors.forename: A M
authors.initials: AM
authors.lastname: Esen
mesh_terms: D000368:Aged; D001281:Atrial Fibrillation / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D000077407:Cilostazol; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D058729:Peripheral Arterial Disease / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology*; D013777:Tetrazoles / Q000008:administration & dosage*; D014665:Vasodilator Agents / Q000008:administration & dosage*
chemical_list: D013777:Tetrazoles; D014665:Vasodilator Agents; D000077407:Cilostazol
keywords: atrial fibrillation; cilostazol; peripheral artery disease; total atrial conduction time